Feb 2, 2021
North Star Holdings Submits Cannabis Research License Applications To DEA

North Star has completed its first physical inspection with the U.S. Drug Enforcement Administration (DEA). North Star intends to be the leader in pharmaceutical grade cannabis production with facilities encompassing over 140 acres of outdoor cultivation and over 500,000 square feet of indoor and greenhouse cannabis cultivation.

“The company believes these applications will position North Star as one of the largest companies in terms of square footage and number of licenses submitted by a single operator for cannabis research in the United States,” said John Kaweske, CEO of North Star. “Our intended clients are universities, pharmaceutical and biotechnology companies. We intend to offer these researchers numerous cannabis genetic varieties to choose from in order to conduct research. Cannabis research may unlock new drug development for future FDA approved treatments.”

The University of Mississippi is the only DEA-licensed cannabis cultivator for research purposes in the United States. North Star is hopeful that 2021 marks a new era of private entities and federal agencies working in cooperation to conduct cannabis research to help create new therapeutics.




  Join us on social media!
GPN January 2022 cover
Get one year of Greenhouse Product News in both print and digital editions for free.


Interested in reading the print edition of GPN?

Subscribe Today »



Be sure to check
out our sister site.
website development by deyo designs